// App-Quantinova.ai

2571 : Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus

Researchers

Presenter

  • Dafna Gladman

Principal Investigators

  • Shawn Rose

  • Kaiyin Fei

  • Yun Gregan

  • Robert Gordon

  • Kim Hung Lo

  • Murray Urowitz

Medical Centers

  • University Health Network, University of Toronto, Toronto, ON, Canada

  • Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

  • Janssen Research and Development, LLC, Spring House, PA

Locations

  • Canada

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved